{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-003165","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2024-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.269496+00:00","generated_at":"2026-06-06T20:36:41.246721+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"PDS Biotech CMO Lauren Wood retires; Kirk Shepard appointed as new CMO","bullets":["Lauren V. Wood, M.D. retired as CMO effective January 22, 2024; departure not related to any disagreement.","Kirk V. Shepard, M.D. appointed as CMO effective January 22, 2024; board-certified oncologist with >30 years industry experience.","Inducement Plan amended to increase reserved shares from 1,100,000 to 2,100,000 shares of common stock.","Dr. Shepard granted nonstatutory stock options to purchase 200,000 shares at $4.49 (closing price on grant date)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-003165","json":"https://secwatch.observer/filing/0001140361-24-003165.json","markdown":"https://secwatch.observer/filing/0001140361-24-003165.md","text":"https://secwatch.observer/filing/0001140361-24-003165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124003165/0001140361-24-003165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124003165/ef20019392_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:36:41.246721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb00e51e8c","claim":"Lauren V. Wood retired as Chief Medical Officer at PDS Biotechnology Corp.","evidence_excerpt":"Effective as of January 22, 2024, Lauren V. Wood, M.D. retired from her position as Chief Medical Officer of PDS Biotechnology Corporation (the “Company”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124003165/0001140361-24-003165-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}